A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
Condition: Arthritis, Psoriatic
MeSH terms: Arthritis; Arthritis, Psoriatic
Intervention: Guselkumab; Placebo
Intervention description: Participants will receive 100 mg of guselkumab as a sterile liquid for SC injection.; Participants will receive matching placebo as SC injection.
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 741.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      The primary purpose of this study is to evaluate the efficacy of guselkumab treatment in
      participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and
      symptoms of PsA.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Have a diagnosis of Psoriatic Arthritis (PsA) for at least 6 months before the first
             administration of study agent and meet Classification criteria for Psoriatic Arthritis
             (CASPAR) at screening

          -  Have active PsA as defined by: at least 5 swollen joints and at least 5 tender joints
             at screening and at baseline, and CRP greater than or equal to (>=) 0.6 milligram per
             deciLitre (mg/dL) at screening from the central laboratory

          -  Have at least 1 of the PsA subsets: distal interphalangeal joint involvement,
             polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans,
             asymmetric peripheral arthritis, or spondylitis with peripheral arthritis
             (confirmation of sacroiliitis should be performed at the screening visit by a locally
             performed pelvic x-ray [single anterior-posterior view] unless a pelvic or SI joint
             x-ray or pelvic magnetic resonance imaging (MRI) has been previously performed.
             Results must be documented)

          -  Have active plaque psoriasis, with at least one psoriatic plaque of >= 2 centimeter
             (cm) diameter or nail changes consistent with psoriasis or documented history of
             plaque psoriasis

          -  Have active PsA despite previous non-biologic disease-modifying antirheumatic drug
             (DMARD), apremilast, and/or nonsteroidal anti-inflammatory drug (NSAID) therapy

        Exclusion Criteria:

          -  Has other inflammatory diseases that might confound the evaluations or benefit of
             guselkumab therapy, including but not limited to rheumatoid arthritis (RA), axial
             spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis),
             systemic lupus erythematosus, or Lyme disease

          -  Has previously received any biologic treatment

          -  Has ever received tofacitinib, baricitinib, filgotinib, peficitinib (ASP015K),
             decernotinib (VX-509), or any other Janus kinase (JAK) inhibitor

          -  Has received any systemic immunosuppressants (eg, azathioprine, cyclosporine, 6
             thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4
             weeks of the first administration of study agent

          -  Is currently receiving 2 or more non-biologic DMARDs (other than methotrexate [MTX],
             sulfasalazine [SSZ], Hydroxychloroquine [HCQ], leflunomide [LEF]) including, but not
             limited to chloroquine, gold preparations, and penicillamine within 4 weeks before the
             first administration of study agent

          -  Has received apremilast within 4 weeks prior to the first administration of study
             agent